UCB

OVERVIEW |  NEWS |  MULTIMEDIA  | RESEARCH

---

UCB Company Summary

COMPANY DATA

	Homepage	www.ucb-group.com/investor_relations/

---

Key Developments: UCB

	UCB (EBR:UCB) Cimzia® Studies Show Significant Clinical Benefits For Mono- And Combination Therapy In Patients With Rheumatoid Arthritis NOV 18, 2008 16:03 - Article Views: 403 UCB (EBR:UCB) * FAST 4WARD showed monotherapy Cimzia® 400 mg, dosed every four weeks, provided significant and effective clinical benefits compared to placebo
	Transparency Notification Of UCB (EBR:UCB) 's Reference Shareholders NOV 1, 2008 07:21 - Article Views: 286 UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:
	UCB (EBR:UCB) Transparency Declaration By Capital Research And Management Company (CRMC) NOV 1, 2008 06:35 - Article Views: 299 UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:
	UCB (EBR:UCB) Transparency Notification Of Wellington Management Company LLP NOV 1, 2008 06:33 - Article Views: 347 UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:
	UCB (EBR:UCB) Fesoterodine Approved In The U.S. NOV 1, 2008 05:33 - Article Views: 475 UCB (EBR:UCB) UCB entitled to receive milestone payment and royalties from Pfizer
	UCB (EBR:UCB) On Track OCT 31, 2008 17:03 - Article Views: 496 UCB (EBR:UCB) * UCB on track to achieve 2008 and 2009 financial outlook * Three new drug launches in nine months * Continued roll-out of strategy * Early research with two new external partnerships
	UCB (EBR:UCB) New Cimzia® Study Shows Rapid Reduction Of Symptoms And Progression Of Rheumatoid Arthritis OCT 31, 2008 11:36 - Article Views: 399 UCB (EBR:UCB) Patients treated with Cimzia®, together with methotrexate (MTX), experienced a rapid and clinically significant improvement in physical function, pain and fatigue as early as week one.
	UCB (EBR:UCB) 's Vimpat® Approved By U.S. FDA As Adjunctive Therapy For Partial Onset Seizures In Adults OCT 29, 2008 17:03 - Article Views: 178 UCB (EBR:UCB) * New antiepileptic drug with a novel mechanism of action * Vimpat® helped people with epilepsy who still had uncontrolled partial onset seizures with current treatment * Vimpat® will be available in the U.S. as oral tablets and intravenous (IV) infusion * Vimpat® should be launched in the U.S. early 2009 by the well-established UCB epilepsy team
	UCB (EBR:UCB) Withdraws EU Marketing Authorisation Application For Lacosamide In Diabetic Neuropathic Pain SEP 26, 2008 02:03 - Article Views: 164 UCB (EBR:UCB) Brussels, BELGIUM, September 25, 2008 at 06:00 pm CET - press release, regulated information: UCB announced today that it is withdrawing the European Marketing Authorisation Application with the European Medicines Agency (EMEA) for Vimpat® (lacosamide) in the treatment of diabetic neuropathic pain.
	Changes In UCB (EBR:UCB) 's Executive Committee SEP 16, 2008 15:03 - Article Views: 226 UCB (EBR:UCB) * Mark McDade appointed Executive Vice President Global Operations succeeding Bill Robinson, to retire

343 COMPANY PROFILE VIEWS

This Page Viewed: (Last 7 Days: 2) (Last 30 Days: 14) (Since Published: 343)